Endocrine Abstracts

The use of Flash Glucose Monitoring system (FGM) for the management of type 1 diabetes mellitus (T1D) is rapidly increasing. FGM enables people with diabetes to regularly track their glucose levels without needing to perform capillary finger-stick measurements (SMBG). Clinical studies have shown improvement of glycemic control and hypoglycemia reduction, as well as better comfort and quality of life in people with type 1 diabetes (T1D) using this technology. Objectives: to asses the degree of achievement of glycemic targets in T1D patients using the flash sensor properly (>70% of the time) in our center.

Methods: We analysed registry data collected at a tertiary diabetes centre in Spain. People with T1D routinely using FGM to manage their diabetes were included in the analysis. Downloaded LibreView data of patients were collected: data regarding glucose management indicator (GMI), time within range 70-180 mg/dl (TIR), coefficient of variation (CV) and hypoglycemic events.

Results: A total of 712 patients were included in the study. 80 patients did not download any sensor data. The downloaded data were prior to 6 months in 20 patients and sensor use was <70% of the time in 116 patients. We analyzed data from patients who used the sensor appropriately (>70% of the time). Data from 488 patients (68.53%) were analyzed. The percentage of patients with a GMI< 7% was 48%, those with CV<36% were 49,8% and those with TIR>70% were 31,6%. All targets were met only in 22,5% of patients. In addition, 87.9% of patients had a high risk of hypoglycemia and 27,5% had experienced at least 1 daily hypoglycemic event.

Conclusions: There is a high percentage of T1D patients using FGM who do not use it properly. Only 15% of TD1 patients with adequate use of the sensor have good glycemic control. Metabolic control in T1D patients should be improved and strategies for proper use of FGM must be implemented.